Showing 4831-4840 of 5570 results for "".
- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- New App Connects Patients and Dermatologistshttps://practicaldermatology.com/news/new-app-connects-patients-and-dermatologists/2458594/The new Dermio app, developed by dermatologist David Soleymani, MD, allows users to confidentially send pictures and videos of rashes, acne and other skin conditions to be diagnosed by a dermatologist in 24 hours or less, according to a recent
- Oculus Innovative Sciences' Microcyn®-based Lasercyn™ Gel Cleared for Post-procedure Usehttps://practicaldermatology.com/news/oculus-innovative-sciences-microcyn-based-lasercyn-gel-cleared-for-post-procedure-use/2458597/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for the company's new Microcyn®-based Lasercyn™ Gel. Under the supervision of a healthcare professional, Lasercyn Gel is int
- Allergan Acquires Topokine Therapeuticshttps://practicaldermatology.com/news/allergan-acquires-topokine-therapeutics/2458596/Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokin
- Personalized Medicine In Action: New Biomarker May Pinpoint Aggressive BCChttps://practicaldermatology.com/news/personalized-medicine-in-action-new-biomarker-may-pinpoint-aggressive-bcc/2458598/A biomarker associated with basal cell carcinoma around the eye may help signal which tumors are likely to be aggressive, report researchers from University of Michigan (U-M) at Ann Arbor. The findings, which appear in JAMA Oncology, may help eliminat
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- SPF30 Sunscreens Delay Melanoma Onset in Mouse Modelhttps://practicaldermatology.com/news/spf30-sunscreens-delay-melanoma-onset-in-mouse-model/2458601/Applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model, report researchers from The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. S